• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

利用稳健归一化在新发帕金森病中创建敏感的认知综合评分:一个示例

Use of Robust Norming to Create a Sensitive Cognitive Summary Score in De Novo Parkinson's Disease: An Illustrative Example.

作者信息

Weintraub Daniel, Brumm Michael C, Kurth Ryan, York Michele K

机构信息

Department of Psychiatry and Neurology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.

Parkinson's Research, Education and Clinical Center, Philadelphia Veterans Affairs Medical Center, Philadelphia, Pennsylvania, USA.

出版信息

Mov Disord. 2025 Mar;40(3):468-477. doi: 10.1002/mds.30111. Epub 2025 Jan 6.

DOI:10.1002/mds.30111
PMID:39760532
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11926498/
Abstract

BACKGROUND

Cognitive impairment is common at all stages of Parkinson's disease (PD), but there is no consensus on which neuropsychological tests to use or how to interpret cognitive battery results. A cognitive summary score (CSS) combines the richness of a neuropsychological battery with the simplicity of a single score.

OBJECTIVE

The objective of this study was to determine whether a CSS created using robust norming can detect early cognitive deficits in de novo, untreated PD.

METHODS

Baseline cognitive data from PD participants and healthy control participants (HCs) in the Parkinson's Progression Markers Initiative were used to (1) create a robust HC subgroup without cognitive decline, (2) generate regression-based z scores for six cognitive measures using this subgroup, and (3) create a CSS by averaging all z scores.

RESULTS

PD participants scored worse than HCs on all cognitive tests, with larger effects when compared with the robust HC subgroup rather than all HCs. Applying internally derived norms, the largest effects were for processing speed/working memory (Cohen's d = -0.55) and verbal episodic memory (Cohen's d = -0.48 and -0.52). Robust norming shifted PD performance from average (CSS z score = -0.01) to low average (CSS z score = -0.40), with a larger effect for the CSS (PD vs. robust HC subgroup; Cohen's d = -0.60) compared with individual tests.

CONCLUSIONS

Patients with PD perform worse cognitively than HCs, particularly in processing speed and verbal memory. Robust norming increases effect sizes and decreases PD scores to expected levels. The CSS outperformed individual tests and may detect cognitive changes in early PD, making it a useful outcome measure in clinical research. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

摘要

背景

认知障碍在帕金森病(PD)的各个阶段都很常见,但对于使用哪些神经心理学测试以及如何解释认知成套测验结果尚无共识。认知综合评分(CSS)将神经心理学成套测验的丰富性与单一分数的简单性结合在一起。

目的

本研究的目的是确定使用稳健常模创建的CSS是否能够检测初发、未治疗的PD患者的早期认知缺陷。

方法

帕金森病进展标志物计划中PD参与者和健康对照参与者(HCs)的基线认知数据用于:(1)创建一个无认知衰退的稳健HC亚组;(2)使用该亚组为六项认知测量生成基于回归的z分数;(3)通过对所有z分数求平均值创建CSS。

结果

在所有认知测试中,PD参与者的得分均低于HCs,与稳健HC亚组相比的效应大于与所有HCs相比。应用内部得出的常模,最大效应出现在加工速度/工作记忆(科恩d值=-0.55)和言语情景记忆(科恩d值=-0.48和-0.52)方面。稳健常模使PD的表现从平均水平(CSS z分数=-0.01)转变为低平均水平(CSS z分数=-0.40),与单个测试相比,CSS的效应更大(PD与稳健HC亚组相比;科恩d值=-0.60)。

结论

PD患者在认知方面的表现比HCs差,尤其是在加工速度和言语记忆方面。稳健常模增加了效应量,并将PD分数降低到预期水平。CSS的表现优于单个测试,可能检测出早期PD的认知变化,使其成为临床研究中一种有用的结果指标。© 2025作者。《运动障碍》由威利期刊有限责任公司代表国际帕金森和运动障碍协会出版。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e007/11926498/b0bf36235073/MDS-40-468-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e007/11926498/b0bf36235073/MDS-40-468-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e007/11926498/b0bf36235073/MDS-40-468-g001.jpg

相似文献

1
Use of Robust Norming to Create a Sensitive Cognitive Summary Score in De Novo Parkinson's Disease: An Illustrative Example.利用稳健归一化在新发帕金森病中创建敏感的认知综合评分:一个示例
Mov Disord. 2025 Mar;40(3):468-477. doi: 10.1002/mds.30111. Epub 2025 Jan 6.
2
Detecting Mild Cognitive Deficits in Parkinson's Disease: Comparison of Neuropsychological Tests.检测帕金森病患者的轻度认知障碍:神经心理学测试比较。
Mov Disord. 2018 Nov;33(11):1750-1759. doi: 10.1002/mds.110. Epub 2018 Sep 14.
3
Assessment of Cognitive-Driven Performance-Based Activities of Daily Living Dysfunction in Parkinson's Disease.评估帕金森病认知驱动的日常生活活动表现障碍。
J Int Neuropsychol Soc. 2020 Apr;26(4):430-440. doi: 10.1017/S1355617719001322. Epub 2019 Dec 11.
4
Defining optimal cutoff scores for cognitive impairment using Movement Disorder Society Task Force criteria for mild cognitive impairment in Parkinson's disease.使用帕金森病轻度认知障碍运动障碍学会工作组标准定义认知障碍的最佳截断分数。
Mov Disord. 2013 Dec;28(14):1972-9. doi: 10.1002/mds.25655. Epub 2013 Oct 9.
5
Memory Phenotypes In Early, De Novo Parkinson's Disease Patients with Mild Cognitive Impairment.早期、新发帕金森病伴轻度认知障碍患者的记忆表型。
Mov Disord. 2023 Aug;38(8):1461-1472. doi: 10.1002/mds.29502. Epub 2023 Jun 15.
6
Altered Cholinergic Innervation in De Novo Parkinson's Disease with and Without Cognitive Impairment.新发帕金森病伴或不伴认知障碍时胆碱能神经支配的改变
Mov Disord. 2022 Apr;37(4):713-723. doi: 10.1002/mds.28913. Epub 2022 Jan 17.
7
REM Sleep Behavior Disorder in Parkinson's Disease: Effects on Cognitive, Psychiatric, and Functional outcomes.帕金森病的 REM 睡眠行为障碍:对认知、精神和功能结果的影响。
J Int Neuropsychol Soc. 2020 Oct;26(9):894-905. doi: 10.1017/S1355617720000430. Epub 2020 May 7.
8
A new CERAD total score with equally weighted z-scores and additional executive and non-amnestic "CERAD-Plus" tests enhances cognitive diagnosis in patients with Parkinson's disease: Evidence from the LANDSCAPE study.新的 CERAD 总分为等权重 z 分数,以及额外的执行和非健忘性“CERAD-Plus”测试,增强了帕金森病患者的认知诊断:来自 LANDSCAPE 研究的证据。
Parkinsonism Relat Disord. 2021 Sep;90:90-97. doi: 10.1016/j.parkreldis.2021.07.034. Epub 2021 Aug 4.
9
Are Standardized Tests Sensitive to Early Cognitive Change in Parkinson's Disease?标准化测试能否敏感检测帕金森病的早期认知变化?
Psychopharmacol Bull. 2023 Feb 28;53(1):19-29.
10
Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease.早期未经治疗的帕金森病患者的认知功能和神经精神症状
Mov Disord. 2015 Jun;30(7):919-27. doi: 10.1002/mds.26170. Epub 2015 Mar 4.

引用本文的文献

1
The Parkinson's Disease Cognitive Composite: Lessons Forgotten from Preclinical Alzheimer's Cognitive Composites.帕金森病认知综合评分:从临床前阿尔茨海默病认知综合评分中遗忘的教训。
Mov Disord. 2025 Jul;40(7):1442-1443. doi: 10.1002/mds.30246. Epub 2025 May 29.

本文引用的文献

1
Huntington study group's neuropsychology working group position on best practice recommendations for the clinical neuropsychological evaluation of patients with Huntington disease.亨廷顿研究小组的神经心理学工作组关于亨廷顿病患者临床神经心理学评估的最佳实践建议的立场。
Clin Neuropsychol. 2024 May;38(4):984-1006. doi: 10.1080/13854046.2023.2267789. Epub 2023 Oct 18.
2
Trial of Solanezumab in Preclinical Alzheimer's Disease.在临床前阿尔茨海默病中进行的 Solanezumab 试验。
N Engl J Med. 2023 Sep 21;389(12):1096-1107. doi: 10.1056/NEJMoa2305032. Epub 2023 Jul 17.
3
Lecanemab in Early Alzheimer's Disease.
早期阿尔茨海默病中的lecanemab
N Engl J Med. 2023 Jan 5;388(1):9-21. doi: 10.1056/NEJMoa2212948. Epub 2022 Nov 29.
4
Management of psychiatric and cognitive complications in Parkinson's disease.帕金森病的精神和认知并发症的管理。
BMJ. 2022 Oct 24;379:e068718. doi: 10.1136/bmj-2021-068718.
5
Level I PD-MCI Using Global Cognitive Tests and the Risk for Parkinson's Disease Dementia.使用整体认知测试的I级帕金森病轻度认知障碍及帕金森病痴呆风险
Mov Disord Clin Pract. 2022 Apr 29;9(4):479-483. doi: 10.1002/mdc3.13451. eCollection 2022 May.
6
Sensitivity of the Preclinical Alzheimer's Cognitive Composite (PACC), PACC5, and Repeatable Battery for Neuropsychological Status (RBANS) to Amyloid Status in Preclinical Alzheimer's Disease -Atabecestat Phase 2b/3 EARLY Clinical Trial.在早期临床试验中,临床前阿尔茨海默病认知复合指标(PACC)、PACC5 和神经心理状态重复电池(RBANS)对淀粉样蛋白状态的敏感性-Atabecestat 2b/3 期
J Prev Alzheimers Dis. 2022;9(2):255-261. doi: 10.14283/jpad.2022.17.
7
Composite cognitive and functional measures for early stage Alzheimer's disease trials.用于早期阿尔茨海默病试验的综合认知和功能测量方法。
Alzheimers Dement (Amst). 2020 May 15;12(1):e12017. doi: 10.1002/dad2.12017. eCollection 2020.
8
Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review.帕金森病非运动症状治疗的研究进展——基于循证医学的评价
Mov Disord. 2019 Feb;34(2):180-198. doi: 10.1002/mds.27602. Epub 2019 Jan 17.
9
The Parkinson's progression markers initiative (PPMI) - establishing a PD biomarker cohort.帕金森病进展标志物计划(PPMI)——建立帕金森病生物标志物队列。
Ann Clin Transl Neurol. 2018 Oct 31;5(12):1460-1477. doi: 10.1002/acn3.644. eCollection 2018 Dec.
10
Detecting Mild Cognitive Deficits in Parkinson's Disease: Comparison of Neuropsychological Tests.检测帕金森病患者的轻度认知障碍:神经心理学测试比较。
Mov Disord. 2018 Nov;33(11):1750-1759. doi: 10.1002/mds.110. Epub 2018 Sep 14.